CompletedPHASE1, PHASE2NCT04388774
Low-Dose Ketamine in Children With ADNP Syndrome
Studying Helsmoortel-Van der Aa syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alexander Kolevzon
- Principal Investigator
- Alexander Kolevzon, MD, MDIcahn School of Medicine at Mount Sinai
- Intervention
- Ketamine(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 5-12 years · All sexes
- Timeline
- 2020 – 2021
Study locations (1)
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04388774 on ClinicalTrials.gov